TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TG Therapeutics Inc (TGTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite mixed financial results, the company shows strong revenue growth, positive clinical data, and a favorable technical setup. The options data indicates bullish sentiment, and the stock has potential for further upside.
The MACD histogram is positive at 0.226 and expanding, indicating bullish momentum. RSI is neutral at 67.691, and moving averages are converging, suggesting a potential breakout. The stock is trading near resistance (R1: 30.922), with support at 28.315. Pre-market price is $30.71, close to resistance, which may indicate further upward movement.
Strong Q4 2025 revenue growth of 78% YoY, driven by BRIUMVI sales and positive clinical data.
Positive sentiment from JPMorgan analyst maintaining an Overweight rating with a $46 price target.
Bullish options sentiment and technical indicators suggesting upward momentum.
Q4 GAAP EPS missed expectations, and net income dropped by 1.26% YoY.
Gross margin declined by 6.51% YoY.
BofA analyst maintains an Underperform rating, citing concerns about sustainability in the biotech sector.
In Q4 2025, TG Therapeutics reported revenue of $192.6 million, up 78% YoY, driven by strong product sales. However, net income dropped by 1.26% YoY to $23.04 million, and EPS declined by 6.67% to $0.14. Gross margin also fell to 80.19%, down 6.51% YoY. Despite these declines, the revenue growth highlights strong operational performance.
Analysts are mixed on TGTX. JPMorgan maintains an Overweight rating with a $46 price target, reflecting confidence in the stock's potential. However, BofA maintains an Underperform rating with a $15 price target, citing concerns about the biotech sector's sustainability. The overall sentiment leans cautiously optimistic.
